Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events
(2009) In Best Practice and Research in Clinical Endocrinology and Metabolism 23(4). p.487-498- Abstract
- Inhibition of dipeptidyl peptidase-4 (DPP-4) is a novel oral treatment for type 2 diabetes. DPP-4 inhibition increases insulin secretion and reduces glucagon secretion by preventing the inactivation of glucagon-like peptide-1 (GLP-1), thereby lowering glucose levels. Several DPP-4 inhibitors are in clinical development; more studies exist for sitagliptin and vildagliptin. They improve metabolic control in type 2 diabetes in monotherapy and also in combination with metformin, sulphonylurea and thiazolidinediones. HbA(1c) is reduced by approximately 0.6-1.1% in studies up to 52 weeks. Similar, although more limited, results were obtained for saxagliptin. DPP-4 inhibitors are safe and tolerable with no increased risk of adverse events... (More)
- Inhibition of dipeptidyl peptidase-4 (DPP-4) is a novel oral treatment for type 2 diabetes. DPP-4 inhibition increases insulin secretion and reduces glucagon secretion by preventing the inactivation of glucagon-like peptide-1 (GLP-1), thereby lowering glucose levels. Several DPP-4 inhibitors are in clinical development; more studies exist for sitagliptin and vildagliptin. They improve metabolic control in type 2 diabetes in monotherapy and also in combination with metformin, sulphonylurea and thiazolidinediones. HbA(1c) is reduced by approximately 0.6-1.1% in studies up to 52 weeks. Similar, although more limited, results were obtained for saxagliptin. DPP-4 inhibitors are safe and tolerable with no increased risk of adverse events compared to placebo and have a low risk of hypoglycaemia. DPP-4 inhibitors are body weight-neutral. The DPP-4 inhibitors are recommended for use in the early stage of type 2 diabetes, in combination with metformin in subjects with inadequate glycaemic control. DPP-4 inhibition may also be used in combination with sulphonylurea and thiazolidinediones and potentially also in combination with insulin. The durability and long-term safety of DPP-4 inhibitors remain to be established. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1483549
- author
- Ahrén, Bo LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Best Practice and Research in Clinical Endocrinology and Metabolism
- volume
- 23
- issue
- 4
- pages
- 487 - 498
- publisher
- Bailliere Tindall Ltd
- external identifiers
-
- wos:000270693600009
- pmid:19748066
- scopus:69949102359
- pmid:19748066
- ISSN
- 1521-690X
- DOI
- 10.1016/j.beem.2009.03.003
- language
- English
- LU publication?
- yes
- id
- 52522673-a6b0-4872-a15b-953fee59e43a (old id 1483549)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19748066?dopt=Abstract
- date added to LUP
- 2016-04-01 14:25:09
- date last changed
- 2024-01-10 03:34:20
@article{52522673-a6b0-4872-a15b-953fee59e43a,
abstract = {{Inhibition of dipeptidyl peptidase-4 (DPP-4) is a novel oral treatment for type 2 diabetes. DPP-4 inhibition increases insulin secretion and reduces glucagon secretion by preventing the inactivation of glucagon-like peptide-1 (GLP-1), thereby lowering glucose levels. Several DPP-4 inhibitors are in clinical development; more studies exist for sitagliptin and vildagliptin. They improve metabolic control in type 2 diabetes in monotherapy and also in combination with metformin, sulphonylurea and thiazolidinediones. HbA(1c) is reduced by approximately 0.6-1.1% in studies up to 52 weeks. Similar, although more limited, results were obtained for saxagliptin. DPP-4 inhibitors are safe and tolerable with no increased risk of adverse events compared to placebo and have a low risk of hypoglycaemia. DPP-4 inhibitors are body weight-neutral. The DPP-4 inhibitors are recommended for use in the early stage of type 2 diabetes, in combination with metformin in subjects with inadequate glycaemic control. DPP-4 inhibition may also be used in combination with sulphonylurea and thiazolidinediones and potentially also in combination with insulin. The durability and long-term safety of DPP-4 inhibitors remain to be established.}},
author = {{Ahrén, Bo}},
issn = {{1521-690X}},
language = {{eng}},
number = {{4}},
pages = {{487--498}},
publisher = {{Bailliere Tindall Ltd}},
series = {{Best Practice and Research in Clinical Endocrinology and Metabolism}},
title = {{Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events}},
url = {{http://dx.doi.org/10.1016/j.beem.2009.03.003}},
doi = {{10.1016/j.beem.2009.03.003}},
volume = {{23}},
year = {{2009}},
}